365 related articles for article (PubMed ID: 32142862)
1. Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Massaquoi MS; Liguore WA; Churchill MJ; Moore C; Melrose HL; Meshul CK
Neuroscience; 2020 May; 433():53-71. PubMed ID: 32142862
[TBL] [Abstract][Full Text] [Related]
2. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Moore C; Meshul CK
Neuroscience; 2015 Apr; 290():454-71. PubMed ID: 25655214
[TBL] [Abstract][Full Text] [Related]
3. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
4. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
[TBL] [Abstract][Full Text] [Related]
5. Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.
Churchill MJ; Pflibsen L; Sconce MD; Moore C; Kim K; Meshul CK
Neuroscience; 2017 Sep; 359():224-247. PubMed ID: 28754312
[TBL] [Abstract][Full Text] [Related]
6. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.
Churchill MJ; Cantu MA; Kasanga EA; Moore C; Salvatore MF; Meshul CK
Neuroscience; 2019 Aug; 414():8-27. PubMed ID: 31220543
[TBL] [Abstract][Full Text] [Related]
8. Effects of sleep disruption on stress, nigrostriatal markers, and behavior in a chronic/progressive MPTP male mouse model of parkinsonism.
Xu M; Bohlen JK; Moore C; Nipper MA; Finn DA; Jones CE; Lim MM; Meshul CK
J Neurosci Res; 2019 Dec; 97(12):1706-1719. PubMed ID: 31535395
[TBL] [Abstract][Full Text] [Related]
9. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
10. 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
Luo D; Shi Y; Wang J; Lin Q; Sun Y; Ye K; Yan Q; Zhang H
Neurosci Lett; 2016 May; 620():43-9. PubMed ID: 27019033
[TBL] [Abstract][Full Text] [Related]
11. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
12. Atractylon, a novel dopamine 2 receptor agonist, ameliorates Parkinsonian like motor dysfunctions in MPTP-induced mice.
Li H; Wang F; Zhou Z; Jiang X; Li F; Feng Y; Liu C; Zhang Y; Fan S; Wu X; Huang C
Neurotoxicology; 2022 Mar; 89():121-126. PubMed ID: 35104500
[TBL] [Abstract][Full Text] [Related]
13. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
17. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
[TBL] [Abstract][Full Text] [Related]
18. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
Ding YX; Xia Y; Jiao XY; Duan L; Yu J; Wang X; Chen LW
Neurochem Res; 2011 Oct; 36(10):1759-66. PubMed ID: 21562748
[TBL] [Abstract][Full Text] [Related]
19. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
20. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]